ebola
outbreak
west
africa
highlight
potenti
larg
diseas
outbreak
caus
emerg
pathogen
gener
consider
focu
prepared
futur
epidem
discuss
driver
strategi
practic
consider
develop
vaccin
outbreak
pathogen
chimpanze
adenovir
chad
vector
develop
vaccin
candid
multipl
infecti
diseas
prostat
cancer
chad
vector
safe
induc
antigenspecif
cellular
humor
immun
age
group
well
circumv
problem
preexist
immun
encount
human
ad
vector
reason
viral
vector
provid
attract
platform
stockpil
vaccin
emerg
deploy
respons
threaten
outbreak
emerg
pathogen
work
alreadi
underway
develop
vaccin
number
outbreak
pathogen
also
review
progress
approach
particularli
lassa
fever
nipah
mer
progress
vector
vaccin
approach
success
rapid
clinic
product
test
ebola
malaria
vaccin
vector
sinc
first
document
report
use
engin
viru
induc
protect
immun
respons
clinic
test
numer
potenti
vaccin
vector
undertaken
broad
rang
diseas
mani
year
preclin
develop
seri
new
vector
vaccin
regimen
demonstr
improv
immunogen
particular
antigenspecif
antibodi
andor
cell
respons
increas
iter
round
vector
vaccin
develop
well
illustr
develop
malaria
vaccin
p
falciparum
encod
metrap
antigen
vaccineinduc
cell
respons
increas
ifng
spotform
cell
per
million
peripher
blood
mononuclear
cell
sfc
dna
vaccin
sfc
singl
vaccin
simian
adenovirusvector
vaccin
tabl
importantli
viral
vector
shown
agelimit
use
compar
cell
respons
observ
follow
vaccin
modifi
vaccinia
ankara
mva
vector
express
influenza
antigen
healthi
older
adult
age
year
compar
younger
adult
popul
age
year
addit
age
deescal
studi
chimpanze
adenoviru
metrap
westafrican
children
demonstr
potent
cell
antibodi
respons
immunis
children
young
week
age
urgent
need
treatment
vaccin
intervent
westafrican
ebola
outbreak
saw
five
vector
vaccin
test
concurr
phase
trial
three
nonrepl
adenovirus
differ
serotyp
mva
vesicular
stomat
viru
vsv
encod
ebolaviru
glycoprotein
gp
vaccin
primarili
test
abil
induc
high
level
antibodi
gp
correl
protect
observ
nonhuman
primat
although
cellmedi
immun
also
shown
play
protect
role
vector
straightforward
directli
compar
antibodi
level
induc
differ
vector
due
rang
assay
employ
differ
group
respons
follow
singl
vaccin
rvsv
detect
within
day
signific
enhanc
antibodi
respons
observ
adenovir
prime
vaccin
follow
mva
boost
humor
immunogen
induc
variou
viral
vector
encod
ebolaviru
ebov
glycoprotein
summaris
tabl
although
initi
develop
platform
induc
cell
respons
singl
vaccin
demonstr
good
antibodi
induct
malaria
antigen
could
enhanc
boost
mva
admva
regimen
induc
igg
respons
maintain
least
day
immunis
primeboost
vaccin
adenovir
mva
vector
vaccin
wellstablish
safe
robust
strategi
induc
cellular
humor
immun
malaria
ebolaviru
addit
mva
boost
increas
magnitud
breadth
cell
respons
fig
tabl
either
vaccin
act
prime
boost
demonstr
novel
phase
ebola
vaccin
trial
multival
mva
bnfilo
vaccin
although
highest
cell
antibodi
respons
mva
observ
four
eightweek
interv
prime
boost
reduc
interv
one
week
still
induc
compar
cell
respons
eightweek
interv
howev
shorter
primeboost
interv
lead
reduct
antibodi
respons
includ
neutralis
antibodi
mva
vector
success
use
boost
respons
adult
induc
vaccin
bcg
infanc
demonstr
potenti
mva
vector
boost
preexist
cell
memori
respons
develop
multival
mva
vector
mva
bnfilo
encod
four
protein
three
ebolaviru
speci
marburg
viru
also
potenti
import
tool
reduc
number
vaccin
product
might
need
manufactur
encod
protect
antigen
sever
strain
pathogen
multipl
pathogen
vaccin
construct
review
larg
genom
mva
allow
insert
larger
amount
foreign
dna
compar
viral
vector
includ
adenovirus
consist
previou
studi
strong
cell
respons
ebov
glycoprotein
observ
singl
administr
significantli
enhanc
mva
boost
undetect
rvsv
vaccin
rvsv
vaccin
assess
efficaci
outbreak
ringvaccin
trial
volunt
stratifi
immedi
delay
vaccin
group
follow
exposur
signific
reduct
ebola
case
day
vaccin
guinea
trial
highlight
need
induc
rapid
immun
respons
outbreak
scenario
singledos
vaccin
remain
manag
option
rapid
respons
outbreak
set
earli
induct
protect
immun
would
prioritis
durabl
howev
immunis
healthcar
worker
first
respond
anticip
potenti
outbreak
futur
durabl
tabl
comparison
cellular
immun
respons
differ
deliveri
method
malaria
antigen
metrap
seven
day
final
vaccin
immunogen
measur
ex
vivo
interferongamma
elispot
use
elispot
method
peptid
pool
lab
would
import
rapid
induct
immun
former
applic
singl
dose
vaccin
desir
wherea
durabl
immun
multidos
regimen
would
like
accept
could
requir
sever
viral
vector
current
potenti
serv
singl
dose
vaccin
platform
purpos
outbreak
prepared
shown
robust
immunogen
clinic
trial
review
howev
order
achiev
high
vaccin
effect
equal
import
consid
paramet
affect
vector
biolog
manufactur
stabil
safeti
vaccin
key
factor
manner
vaccin
antigen
encod
express
adenovir
vector
vaccin
antigen
typic
place
control
heterolog
strong
promot
encod
independ
express
cassett
insert
wellcharacteris
locat
adenovir
genom
commonli
locu
concurr
delet
adenovir
gene
locu
render
viru
replic
incompet
vector
product
therefor
take
place
complement
cell
line
express
gene
typic
genet
engin
method
antigen
insert
adenovir
vector
includ
plasmidbas
homolog
recombin
e
coli
bacteri
artifici
chromosom
bac
base
recombin
vitro
gateway
recombin
placement
antigen
express
cassett
within
viral
genom
lead
denovo
express
antigen
vaccin
target
cell
turn
result
strong
humor
well
cellular
immun
respons
antigen
recent
capsidincorpor
approach
shown
promis
induct
antigenspecif
antibodi
use
modifi
adenovir
vector
antigen
epitop
entir
antigen
engin
part
adenovir
capsid
protein
thu
display
surfac
viral
vector
recognit
immun
system
howev
capsiddisplay
strategi
yet
evalu
clinic
trial
review
focu
tradit
engin
adenovir
vector
antigen
cassett
locu
first
adenovir
vaccin
vector
develop
base
human
adenoviru
serotyp
speci
c
adenoviru
commonli
infect
human
howev
found
preexist
antibodi
present
larg
proport
human
popul
could
significantli
dampen
humor
cellular
immun
respons
vaccin
antigen
variou
strategi
sinc
explor
circumv
problem
use
altern
human
serotyp
reengin
capsid
prevent
antibodi
recognit
use
simian
adenovir
vector
preexist
immun
discuss
chimpanze
adenovir
vector
chad
success
use
clinic
trial
varieti
diseas
chad
nonenvelop
virus
mean
antigen
eg
membran
glycoprotein
present
surfac
vector
express
high
level
vector
enter
target
cell
vaccin
individu
contrast
vsvbase
vaccin
vector
envelop
virus
design
incorpor
glycoprotein
antigen
viral
lipid
membran
thu
display
antigen
viru
surfac
addit
express
upon
entri
target
cell
crucial
vsvbase
vector
carri
heterolog
glycoprotein
antigen
gener
delet
endogen
glycoprotein
vsvg
impli
fall
vaccin
antigen
fulfil
role
function
viral
fusion
protein
essenti
compon
vector
propag
manufactur
well
target
cell
entri
import
requir
function
inher
affect
choic
antigen
vsvbase
vector
viral
glycoprotein
antigen
either
function
eg
nipah
viru
glycoprotein
g
need
glycoprotein
f
incorpor
vsv
membran
without
modif
eg
hiv
env
addit
adenovir
vector
equal
well
encod
antigen
membranebound
glycoprotein
eg
ebolaviru
nucleoprotein
hiv
gag
vsv
vector
carri
antigen
reli
endogen
glycoprotein
vsvg
viral
entri
sinc
fulllength
vsvg
protein
implic
neurotrop
genet
attenu
vector
carri
truncat
vsvg
develop
accept
safeti
profil
healthi
adult
thu
weigh
characterist
two
clinic
advanc
vector
emerg
prepared
platform
becom
appar
vector
biolog
signific
implic
vaccin
safeti
specif
tissu
tropism
replic
compet
viral
vector
taken
consider
intuit
replicationdefici
vector
chad
carri
less
safeti
risk
replic
compet
albeit
attenu
vector
vsv
sinc
inabl
replic
prevent
dissemin
vector
throughout
bodi
accordingli
transgen
express
replicationdefici
adenovir
vector
shown
confin
inject
site
drain
lymph
node
wherea
recent
phase
iii
trial
rvsvzebov
found
evid
viral
vector
replic
synovi
fluid
skin
lesion
presum
result
ebolaviru
glycoproteinspecif
tissu
tropism
vaccin
find
underlin
difficulti
predict
safeti
profil
vsvbase
vaccin
sinc
tissu
tropism
highli
depend
chosen
glycoprotein
antigen
contrast
adenovir
vector
wellcharacteris
safeti
profil
across
rang
age
group
larg
independ
natur
antigen
lastli
vector
biolog
may
also
significantli
impact
vaccin
manufactur
deliveri
emerg
prepared
stockpil
vaccin
might
need
produc
scale
million
dose
option
quickli
increas
manufactur
perhap
million
dose
case
outbreak
depend
specif
pathogen
two
clinic
advanc
platform
vsv
adenovirus
latter
like
meet
requir
easili
gmpcompliant
largescal
adenovir
vector
product
facil
exist
mani
countri
relat
regular
use
adenovir
vector
prophylact
vaccin
also
cancer
genetherapi
trial
one
potenti
drawback
chadbas
viral
vector
compar
human
ad
vector
need
vector
optimis
cell
line
engin
ensur
high
viral
yield
viru
product
exampl
chad
vector
may
need
contain
certain
gene
order
grow
high
titer
current
cell
line
demonstr
vector
altern
produc
cell
line
engin
increas
viral
yield
howev
need
optimis
hurdl
largescal
manufactur
far
gmpcompliant
vsvvector
product
also
develop
recent
year
scalabl
manufactur
rvsv
possibl
stockpil
produc
vector
stabil
storag
deploy
critic
viral
vector
vaccin
stabl
year
c
c
cold
chain
requir
distribut
storag
adenovir
vector
one
studi
assess
recent
deploy
rvsvzebov
vaccin
observ
signific
loss
viral
titr
temperatur
c
week
wherea
adenovir
vector
shown
stabl
day
room
temperatur
sucros
buffer
addit
sensit
vsvbase
vaccin
ph
chang
presum
depend
specif
envelop
glycoprotein
ie
vaccin
antigen
overal
vaccin
stabil
term
temperatur
ph
rang
would
therefor
like
variabl
across
panel
put
vsvbase
outbreak
vaccin
sinc
glycoprotein
differ
vaccin
vaccin
case
adenovir
vector
vaccin
hand
variat
stabil
expect
minim
sinc
vaccin
antigen
present
viral
capsid
composit
viru
particl
would
similar
across
differ
vaccin
note
new
approach
thermostabilis
recent
develop
adenovir
vector
immobil
viral
particl
sugar
glass
filter
use
biocompat
addit
slow
degrad
viru
particl
improv
expect
signific
impact
deploy
vector
vaccin
challeng
climat
subsaharan
africa
human
popul
preexist
immun
simianderiv
adenovir
vector
unsurprisingli
less
preval
immun
human
adenovirus
antibodi
simian
vector
appear
particularli
rare
antivector
immun
backbon
simian
virus
increas
vaccin
rel
shortliv
result
reus
vector
success
boost
month
clinic
trial
tradit
approach
vector
vaccin
design
identifi
immunogen
antigen
pathogen
construct
vector
chosen
platform
assess
immunogen
efficaci
murin
model
prior
test
higher
speci
progress
next
stage
vaccin
develop
signific
obstacl
approach
pathogen
must
infecti
rodent
efficaci
vaccin
assess
preclin
therefor
data
may
reli
mouseadapt
chimer
pathogen
tabl
summaris
common
mous
model
evalu
candid
vaccin
outbreak
pathogen
case
mer
cov
sar
cov
preclin
vaccin
candid
could
test
murin
model
mous
adapt
strain
viru
newli
emerg
pathogen
establish
mous
model
could
take
signific
time
particular
evalu
numer
viral
isol
serial
passag
viru
mice
altern
use
neonat
mice
knockout
mice
eg
ifnabr
requir
mimic
human
diseas
ebola
marburg
lassa
nipah
zika
virus
mice
express
human
receptor
mer
cov
mous
lung
could
infect
mice
mer
cov
achiev
mous
model
may
prove
use
drug
discoveri
signific
compon
immun
respons
compromis
unlik
protect
observ
preclin
studi
consist
protect
immun
respons
requir
human
econom
achiev
strategi
tradit
approach
vaccin
develop
deploy
would
focu
manufactur
small
stockpil
vaccin
use
common
platform
technolog
chad
vector
vaccin
provid
good
exampl
suitabl
vaccin
platform
identifi
one
signific
interest
r
blueprint
process
overal
strategi
would
gener
suitabl
stockpil
emerg
respons
use
previous
demonstr
safeti
immunogen
vaccin
phase
ii
trial
target
geograph
region
product
could
store
relev
locat
diseas
event
outbreak
emerg
could
deploy
ring
vaccin
program
similar
employ
phase
iii
trial
guinea
rvsv
zebov
vaccin
west
african
ebola
outbreak
deploy
would
need
made
provis
polici
use
unapprov
medicin
product
fda
expand
access
program
also
known
compassion
use
emerg
use
legisl
would
requir
fulfil
certain
condit
includ
compar
satisfactori
therapi
avail
risk
harm
vaccin
greater
risk
diseas
suffici
evid
safeti
effect
product
support
use
given
circumst
context
vaccin
outbreak
pathogen
base
welldevelop
platform
chad
vector
evid
efficaci
relev
anim
model
would
like
gain
approv
use
limit
set
base
research
manufactur
clinic
trial
cost
vector
vaccin
develop
ebola
vaccin
might
stockpil
million
per
diseas
repres
fraction
cost
bring
vaccin
licensur
deploy
would
provid
efficaci
data
human
requir
approv
nation
regul
increas
likelihood
vaccin
progress
later
stage
develop
improv
respons
epidem
publish
list
nine
diseas
requir
urgent
vaccin
r
prevent
public
health
emerg
futur
list
revis
key
characterist
diseas
prioritis
summaris
tabl
process
prioritis
diseas
took
account
properti
caus
pathogen
eg
transmiss
hostbas
factor
immunopatholog
clinic
aspect
includ
eas
accur
diagnosi
avail
countermeasur
mortal
public
health
capac
epidemiolog
factor
research
develop
prioriti
diseas
includ
develop
suitabl
diagnost
test
assess
potenti
treatment
identif
key
knowledg
gap
product
platform
behaviour
intervent
acceler
vaccin
develop
prepar
suffici
quantiti
safe
efficaci
vaccin
potenti
outbreak
pathogen
extrem
effect
strategi
howev
lack
access
dedic
longterm
fund
hamper
vaccin
develop
outbreak
pathogen
recent
decad
well
limit
number
new
vaccin
develop
number
facil
capac
biomanufactur
vaccin
also
limit
signific
issu
outbreak
prepared
addit
recognis
gener
applic
platform
technolog
rapid
vaccin
develop
requir
set
identifi
prioritis
lead
platform
address
issu
coalit
epidem
prepared
innov
cepi
launch
januari
bring
togeth
funder
includ
wellcom
trust
bill
melinda
gate
foundat
govern
norway
germani
japan
other
initi
fund
million
european
commiss
also
pledg
cofund
million
fund
due
confirm
govern
india
end
fund
initi
focu
nipah
lassa
mer
virus
aim
bring
two
candid
vaccin
develop
diseas
cepi
also
aim
promot
technic
institut
platform
improv
respons
futur
epidem
approach
undertaken
cepi
advanc
vaccin
develop
diseas
research
date
limit
larg
part
due
lack
market
potenti
vaccin
conjunct
huge
cost
involv
long
period
time
provid
vaccin
preclin
develop
licensur
estim
upward
million
million
per
vaccin
therefor
fund
requir
licens
vaccin
prioriti
diseas
highlight
blueprint
would
run
mani
billion
dollar
opportun
assess
efficaci
vaccin
human
would
rare
although
ebola
viru
diseas
evd
describ
sinc
outbreak
began
larger
previou
episod
combin
potenti
due
mutat
glycoprotein
occur
immedi
prior
rapid
increas
number
evd
case
although
suffici
advanc
deploy
immedi
outbreak
sever
vaccin
ebolavirus
alreadi
manufactur
good
manufactur
practic
gmp
standard
provid
rare
opportun
undertak
phase
trial
rapidli
assess
efficaci
diseas
outbreak
provid
muchneed
impetu
improv
pandem
prepared
emerg
pathogen
end
three
identifi
virus
target
vaccin
develop
cepi
known
potenti
caus
outbreak
high
mortal
merscov
nipah
viru
lassa
viru
nipah
viru
niv
recentlyrecognis
highli
pathogen
zoonot
paramyxoviru
caus
sever
diseas
man
high
associ
fatal
rate
outbreak
occur
malaysia
singapor
india
almost
annual
occurr
bangladesh
humantohuman
transmiss
common
bangladesh
also
document
india
sever
speci
pteropid
fruit
bat
known
host
reservoir
niv
accumul
evid
niv
paramyxovirus
circul
worldwid
bat
high
fatal
rate
direct
infect
natur
reservoir
infect
follow
amplif
suscept
domest
livestock
pig
document
humantohuman
transmiss
potenti
abil
transvers
globe
emphasis
pandem
potenti
niv
clinic
approv
vaccin
niv
howev
one
therapeut
approach
monoclon
antibodi
therapi
recent
complet
phase
clinic
trial
result
still
report
monoclon
antibodi
treatment
may
efficaci
short
window
postexposur
treatment
option
suitabl
largescal
use
vaccin
develop
key
research
focu
prevent
nivmedi
diseas
advantag
number
anim
model
niv
infect
use
vaccin
develop
program
consid
suffici
mirror
nivinduc
pathogenesi
observ
human
eg
hamster
ferret
african
green
monkey
agm
model
vaccinemedi
cellular
immun
demonstr
play
role
protect
preclin
model
niv
infect
advanc
vaccin
modal
demonstr
clear
efficaci
across
multipl
anim
model
primarili
induc
humor
immun
solubl
glycoprotein
sg
subunit
vaccin
relat
henipaviru
hendra
viru
hev
extens
studi
vaccin
protect
ferret
agm
experiment
challeng
niv
hev
primeboost
regimen
adjuv
hevsg
subunit
protein
efficaci
stringent
niv
challeng
model
across
rang
dose
prechalleng
neutralis
antibodi
titr
low
hev
sg
vaccin
equivac
hev
licens
vaccin
hors
australia
hev
number
viral
vector
vaccin
also
test
show
promis
immunogen
andor
efficaci
nivmedi
diseas
includ
poxviru
canarypoxviru
alvac
strain
vesicular
stomat
viru
vsv
rabi
viru
rabv
adenoassoci
viru
aav
newcastl
diseas
viru
ndv
venezuelan
equin
enceph
viru
veev
topic
recent
comprehens
review
lassa
viru
lasv
medic
relev
arenaviru
produc
condit
rang
asymptomat
infect
lethal
haemorrhag
fever
lassa
fever
lf
annual
lasv
appear
infect
individu
mortal
rate
rang
excess
outbreak
lf
endem
zoonosi
part
west
africa
includ
nigeria
liberia
sierra
leon
guinea
recent
studi
highlight
spread
lasv
surround
area
eg
mali
benin
ghana
epidemiolog
suggest
efficaci
trial
lassa
fever
vaccin
could
conduct
success
countri
nigeria
sierra
leon
common
african
rat
mastomi
natalensi
zoonot
reservoir
lasv
thought
facilit
eas
lasv
spread
human
despit
recurr
high
diseas
incid
associ
signific
morbid
mortal
approv
vaccin
current
lf
treatment
reli
support
care
avail
administr
antivir
drug
ribavirin
continu
unmet
need
medic
intervent
curb
spread
lasv
avert
morbid
mortal
associ
potenti
viral
dissemin
larg
geograph
area
due
zoonot
reservoir
first
clinic
avail
vaccin
prevent
arenaviru
haemorrhag
fever
candid
liveattenu
vaccin
junin
viru
infect
avail
argentin
nation
immun
plan
unfortun
develop
lasv
vaccin
progress
rapidli
cellular
immun
thought
critic
surviv
lf
infect
earli
cell
activ
associ
better
clinic
outcom
recent
studi
focus
earli
stage
lf
nonhuman
primat
nhp
confirm
previou
observ
earli
strong
tcell
respons
associ
effect
control
viru
replic
recoveri
fatal
lasv
infect
nhp
associ
lack
peripher
tcell
activ
also
demonstr
vaccin
strategi
primarili
aim
elicit
lasvspecif
humor
immun
effect
eg
gammairradi
lasv
develop
lasv
vaccin
involv
number
differ
platform
technolog
includ
nonrepl
vaccin
approach
inactiv
lasv
viru
viruslik
particl
vlp
dna
vaccin
well
replicationcompet
vaccin
strategi
recombin
reassort
viral
vector
vaccin
four
replicationcompet
lasv
vaccin
candid
extens
studi
base
vaccinia
viru
vesicular
stomat
viru
mopeia
viru
mopv
yellow
fever
viru
yfv
vector
vaccin
candid
test
differ
anim
model
includ
nhp
efficaci
test
anim
model
mimic
major
pathophysiolog
immunolog
featur
human
lf
prerequisit
licensur
rodent
obviou
first
speci
establish
immunogen
lasv
rodent
host
reservoir
respons
lasv
vari
depend
mous
strain
age
inocul
rout
rodent
suitabl
valid
lf
diseas
model
guinea
pig
sensit
model
studi
lung
patholog
common
marmoset
cm
surrog
studi
liver
involv
howev
lasvinfect
rhesu
cynomolgu
monkey
consid
goldstandard
model
avail
relev
challeng
model
human
lf
yfv
vaccin
strain
genet
manipul
express
lasv
glycoprotein
design
control
diseas
yf
lf
area
overlap
incid
west
africa
protect
guinea
pig
fail
protect
marmoset
genet
unstabl
addit
recombin
vesicular
stomat
viru
rvsv
express
lasv
glycoprotein
protect
nonhuman
primat
challeng
protect
steril
lasv
viremia
could
measur
postinfect
lasv
mopv
close
relat
old
world
arenavirus
exchang
genom
segment
reassort
coinfect
clone
encod
major
antigen
lasv
also
mopv
antigen
preclin
marmoset
guinea
pig
surviv
otherwis
fatal
lasv
infect
recent
studi
demonstr
sivinfect
rhesu
macaqu
respond
well
vaccin
surviv
challeng
heterolog
lethal
arenaviru
strain
lcmvwe
indic
safe
immunogen
immunocompromis
anim
anoth
vaccin
vector
prove
effect
guinea
pig
lasv
challeng
venezuelan
equin
enceph
viru
rvee
replicon
particl
express
gp
np
anim
fulli
protect
lasv
challeng
primeboostboost
immun
vector
one
promis
vaccin
vaccinia
viru
encod
lasv
glycoprotein
nonhuman
primat
vaccin
vaccin
candid
protect
challeng
howev
despit
sever
promis
vaccin
candid
preclin
evalu
none
yet
advanc
clinic
trial
human
sever
novel
coronavirus
emerg
last
decad
caus
outbreak
mainli
middl
east
region
asia
saudi
arabia
jordan
qatar
china
particular
epidem
sever
acut
respiratori
syndrom
sar
report
start
china
caus
case
mortal
depend
age
caus
agent
identifi
novel
coronaviru
sar
cov
previous
identifi
infecti
human
bat
civet
natur
reservoir
middl
eastern
respiratori
syndrom
mer
first
report
man
becam
ill
saudi
arabia
isol
anoth
novel
coronaviru
follow
known
mer
cov
subsequ
caus
nearli
case
death
dromedari
camel
reservoir
although
transmiss
also
occur
human
human
strategi
produc
effect
coronaviru
vaccin
focuss
express
either
spike
protein
nucleocapsid
protein
case
combin
rang
vector
includ
rabi
virus
vsv
vee
review
report
recent
workshop
riyadh
countermeasur
mer
cov
bring
togeth
funder
public
health
expert
research
conclud
progress
vaccin
develop
still
hinder
lack
anim
model
evalu
efficaci
small
anim
natur
express
function
form
dipeptidyl
peptidas
receptor
howev
transgen
mice
express
human
suscept
infect
despit
advanc
mous
model
like
less
use
assess
immun
correl
larger
anim
model
rhesu
macaqu
common
marmoset
exhibit
sever
clinic
syndrom
observ
human
mva
chad
viral
vector
mer
reach
gmp
manufactur
dna
vaccin
test
clinic
trial
progress
develop
chimpanze
adenoviru
vector
outbreak
pathogen
may
first
case
outbreak
evd
report
ba
uel
provinc
democrat
republ
congo
drc
area
share
border
central
african
republ
particularli
remot
difficult
access
caus
speci
identifi
zair
ebolaviru
rvsvzebov
vaccin
consid
time
write
deploy
ring
vaccin
design
protect
contact
frontlin
healthcar
worker
hcw
fresh
outbreak
th
occur
drc
highlight
potenti
util
vaccin
protect
hcw
particularli
remot
locat
present
signific
logist
challeng
respond
contain
outbreak
maintain
current
momentum
develop
vaccin
outbreak
pathogen
crucial
simian
adenovirus
uniqu
fit
purpos
effect
vaccin
platform
small
part
due
predict
safeti
profil
stabil
manufactur
importantli
owe
immunogen
therefor
singleantigen
pathogenspecif
chad
vector
vaccin
could
suitabl
singl
dose
approach
rapid
induct
protect
immun
outbreak
durabl
protect
potenti
first
respond
chad
prime
mva
boost
approach
could
effect
novel
vaccin
outbreak
pathogen
develop
rang
simian
adenoviru
serotyp
includ
review
human
vector
applic
pipelin
approach
develop
vaccin
outbreak
pathogen
greatli
acceler
output
candid
vaccin
key
process
gener
construct
product
viru
stock
defin
preclin
immunogen
gmp
manufactur
substanti
standard
approach
current
adopt
least
twelv
potenti
outbreak
pathogen
use
standard
preclin
process
tabl
sever
advanc
gmp
manufactur
clinic
test
latter
includ
vaccin
merscov
rift
valley
fever
viru
zika
viru
chikungunya
viru
key
bottleneck
approach
identif
vaccin
antigen
avail
appropri
anim
model
diseas
prepar
made
counter
futur
threat
knowledg
emerg
pathogen
requir
yet
detail
epidemiolog
surveil
mani
infecti
diseas
remain
limit
region
incid
greatest
recent
data
suggest
around
tabl
statu
chimpanze
adenoviru
vector
chad
vaccin
develop
rang
outbreak
pathogen
jenner
institut
univers
oxford
may
genet
background
vector
speci
e
modifi
chimpanze
adenoviru
base
isol
antigen
insert
locu
via
gateway
recombin
preclin
immunogen
test
mice
typic
receiv
singledos
emerg
infecti
diseas
zoonot
major
origin
wildlif
requir
surveil
among
livestock
anim
wildlif
speci
well
human
although
ebola
outbreak
occur
sporad
sinc
pace
vaccin
develop
ebola
slow
vaccin
undergo
preclin
evalu
year
start
phase
clinic
trial
outbreak
provid
much
need
momentum
public
health
expert
research
commun
improv
prepared
futur
epidem
order
continu
improv
prepared
futur
outbreak
epidemiolog
surveil
vaccin
develop
need
acceler
substanti
